Oblique Therapeutics presents tumor growth inhibition and Treg-lowering data for OT-1096 in humanized mouse TNBC model at oncology congress ESMO
Oblique Therapeutics opens office in Stockholm, Sweden
We are hiring!
Research results on advanced cancer treatment published in renowned medical journal
Oblique Therapeutics is featured in SvD ”Kampen mot cancer” (only in swedish)
Oblique Therapeutics has yet again received grants from Vinnova
Oblique Therapeutics’ platform technology will be presented at the DDIP in Munich